Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune data on the participants after 2 months.
| Condition |
|---|
|
Schizophrenia Schizoaffective Disorder Delusional Disorder |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus |
blood samples are collected, stored at minus 70 degree C and analyzed in batches.
| Estimated Enrollment: | 200 |
| Study Start Date: | August 2003 |
| Estimated Study Completion Date: | June 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia. As part of the study, we collect neuroendocrine-immune data on patients with first episode, treatment naive psychosis, patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune on the participants (patients and controls) after 2 months. Thus, our study does not control treatment. Patients take treatment in consultation with their physician. Some of them even decide not to take any medications. At the 2nd visit, we do ask them about the the medications they are taking if any.
Eligibility| Ages Eligible for Study: | 14 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Probability Sample |
Patients with psychosis
Inclusion Criteria:
- Psychotic disorder as per DSM-IV criteria of the American Psychiatric Association
Exclusion Criteria:
- Diabetes, type 1 or 2
- Prominent substance abuse (i.e. psychotic symptoms attributable entirely to substance use)
- Age above 50 or age below 14
Contacts and Locations| Contact: Ripu D Jindal, MD | 412 512 9516 | jindalr@upmc.edu |
| United States, Pennsylvania | |
| University of Pittsburgh | Recruiting |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| Contact: Richard S Guido, MD 412-383-1480 guidrs@upmc.edu | |
| Principal Investigator: Ripu D Jindal, MD | |
| Sub-Investigator: Matcheri S Keshavan, MD | |
| Sub-Investigator: Kevin Eklund, BSN | |
| Sub-Investigator: Alicia A Thomas, BS | |
| Principal Investigator: | Ripu D Jindal, MD | University of Pittsburgh |
More Information
No publications provided
| Responsible Party: | Ripu Jindal, MD Clinical Assistant Professor, University of Pittsburgh |
| ClinicalTrials.gov Identifier: | NCT00222807 History of Changes |
| Other Study ID Numbers: | 0306110 |
| Study First Received: | September 13, 2005 |
| Last Updated: | February 16, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by University of Pittsburgh:
|
schizophrenia, psychosis, type 2 diabetes mellitus |
Additional relevant MeSH terms:
|
Schizophrenia, Paranoid Delusions Diabetes Mellitus Psychotic Disorders Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Behavioral Symptoms Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 23, 2013